Literature DB >> 11093595

The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis.

H Alexanderson1, C H Stenström, G Jenner, I Lundberg.   

Abstract

The objective was to investigate whether a 12-week resistive home exercise program in addition to conventional medical treatment could be safely performed regarding muscle inflammation, muscle function, and quality of life in patients with active polymyositis (PM) or dermatomyositis (DM). Eleven patients diagnosed with active PM or DM were included. Muscle biopsies and Magnetic Resonance Imaging (MRI) of the thighs were performed. Quality of life, function, and subjective global disease impact (SGDI) were assessed and creatine phosphokinase levels (CPK) were analysed. The patients exercised with the exercise program for 15 minutes and took a 15-minute walk five days a week for 12 weeks. After the exercise period there was no sign of increased muscle inflammation. The group showed significantly improved function and quality of life compared to the start of study. It seems that this exercise program safely can be employed in patients with active PM or DM, and we suggest that physical exercise should be included in the rehabilitation of these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093595     DOI: 10.1080/030097400447679

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  25 in total

Review 1.  The relevance of applying exercise training principles when designing therapeutic interventions for patients with inflammatory myopathies: a systematic review.

Authors:  Pierrette Baschung Pfister; Eling D de Bruin; Bernadette C Tobler-Ammann; Britta Maurer; Ruud H Knols
Journal:  Rheumatol Int       Date:  2015-08-14       Impact factor: 2.631

Review 2.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

Review 3.  Exercise: an important component of treatment in the idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 4.  Strength training and aerobic exercise training for muscle disease.

Authors:  Nicoline Bm Voet; Elly L van der Kooi; Baziel Gm van Engelen; Alexander Ch Geurts
Journal:  Cochrane Database Syst Rev       Date:  2019-12-06

Review 5.  Exercise in inflammatory myopathies, including inclusion body myositis.

Authors:  Helene Alexanderson
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 6.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

Review 7.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

8.  An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility.

Authors:  Chiara M Antonioli; Giovanni Bua; Anna Frigè; Katia Prandini; Sara Radici; Mirko Scarsi; Elisabetta Danieli; Andrea Malvicini; Paolo Airo
Journal:  Clin Rheumatol       Date:  2008-09-16       Impact factor: 2.980

Review 9.  New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis.

Authors:  Li Alemo Munters; Helene Alexanderson; Leslie J Crofford; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2014-07       Impact factor: 4.592

Review 10.  Idiopathic inflammatory myopathies: a treatment update.

Authors:  Chester V Oddis
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.